Should I Buy CUE? CUE 2026 Analysis

Should You Buy Cue Biopharma Inc (CUE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.320

1 Day change

1.27%

52 Week Range

1.540

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price is in a clear downtrend and is breaking below key support (S1 0.318) with bearish moving averages.
No Intellectia edge today: AI Stock Picker = no signal; SwingMax = no recent signal, so there’s no strong tactical “buy now” trigger.
With no near-term news catalysts and weak recent quarter growth trends, odds favor further downside rather than an immediate rebound (pattern-based projection points to additional declines over 1D/1W/1M).
For an impatient investor unwilling to wait for better setups, the current tape does not justify an entry; best action is to avoid/exit.

Technical Analysis

Trend: Bearish (SMA_200 > SMA_20 > SMA_5) confirms persistent weakness.
Momentum: RSI(6)=32.41 (near oversold but not a confirmed reversal); MACD histogram slightly positive (0.00214) but contracting, suggesting any bounce is losing steam.
Levels: Price 0.3005 is below pivot 0.375 and below S1 0.318; next support S2 ~0.282. Overhead resistance starts at ~0.432 (R1).
Near-term bias: Break below S1 increases probability of a push toward S2 before any durable rebound attempt.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open interest is extremely call-heavy (OI put/call = 0.05), which can reflect speculative upside interest, but it can also be stale positioning.
Activity: Options volume is effectively zero today (put/call volume = 0.0; calls=0, puts=0), so there is no strong real-time sentiment signal from flow.
Volatility: Very elevated (30D IV ~306.94 vs HV ~168.3). IV has been drifting down vs 5D/10D averages, but absolute volatility remains extreme—market is pricing large moves.

Technical Summary

Sell

Buy

Positive Catalysts

- NULL identified in the last week (no news items provided).
- A short-term technical bounce is possible due to near-oversold RSI, but this is not a catalyst-driven setup.

Neutral/Negative Catalysts

- Price is actively weak today (regular session -8.94%) and trading below a key support zone, which often attracts additional selling.
- No recent news/catalysts to change the narrative in the near term.
- Pattern-based outlook provided: ~80% chance of additional downside across 1D/1W/1M horizons.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 2.149M, down -35.58% YoY (top-line contraction).
Net income: -7.448M (loss), down -14.00% YoY (still meaningfully unprofitable).
EPS: -0.07, down -58.82% YoY (earnings quality deteriorated).
Gross margin: 100 (reported), but overall results still show weakening growth and continued losses.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so a recent trend summary can’t be confirmed.
Wall Street pros/cons view (based strictly on provided data): Pros: none evidenced by coverage updates; Cons: shrinking revenue and deeper EPS decline, plus a bearish technical trend with no catalyst support.

Analyst Rating

Wall Street analysts forecast CUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CUE is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 0.316

Low

Averages

High

Current: 0.316

Low

Averages

High

Lucid Capital

Dev Prasad

Buy

initiated

AI Analysis

2025-08-25

Reason

Lucid Capital

Dev Prasad

Price Target

AI Analysis

2025-08-25

initiated

Buy

Reason

Lucid Capital analyst Dev Prasad initiated coverage of Cue Biopharma with a Buy rating and $4 price target. The company's lead asset CUE-401 is a novel bispecific for autoimmune disease, the analyst tells investors in a research note. The firm believes preclinical data show "strong mechanistic validation and broad efficacy" across autoimmune models.

Citizens Capital Markets

Reni Benjamin

Buy

Reiterates

2025-04-02

Reason

Citizens Capital Markets

Reni Benjamin

Price Target

2025-04-02

Reiterates

Buy

Reason

CUE Should I Buy

CUE Should I Buy

Should You Buy Cue Biopharma Inc (CUE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch